Literature DB >> 15380349

The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.

Donna E Hogge1, Michaela Feuring-Buske, Brigitte Gerhard, Arthur E Frankel.   

Abstract

Addition of cytosine arabinoside (Ara-C) to truncated diphtheria toxin (DT388) fused to granulocyte macrophage-colony stimulating factor (GMCSF) or interleukin-3 (IL3) was studied in a NOD/SCID mouse model of human AML. Ara-C alone did not reduce the % human AML cells in mouse bone marrow (BM). DT388IL3 or DT388GMCSF alone reduced but did not eradicate engraftment for two of four and two of three samples, respectively. In contrast, Ara-C with DT388IL3 eliminated AML from mouse BM with one of four samples while DT388GMCSF with Ara-C eliminated or reduced AML cells as compared to mice receiving either agent alone with two of three samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380349     DOI: 10.1016/j.leukres.2004.03.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

Review 2.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

3.  The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3.

Authors:  Yanjun Zhang; Rong Liu; Dongmei Fan; Rizan Shi; Ming Yang; Qingfang Miao; Zhao-Qun Deng; Jun Qian; Yongsu Zhen; Dongsheng Xiong; Jianxiang Wang
Journal:  Cancer Biol Ther       Date:  2015-07-17       Impact factor: 4.742

Review 4.  Tagraxofusp: First Global Approval.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

5.  A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.

Authors:  A Ray; D S Das; Y Song; V Macri; P Richardson; C L Brooks; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2017-05-08       Impact factor: 11.528

6.  Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Francine M Foss; Madeleine Duvic; Paul H Neville; David M Neville
Journal:  Haematologica       Date:  2015-03-20       Impact factor: 9.941

Review 7.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

8.  AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.

Authors:  Adedayo Oke; Daniel Pearce; Robert W Wilkinson; Claire Crafter; Rajesh Odedra; Jamie Cavenagh; Jude Fitzgibbon; Andrew T Lister; Simon Joel; Dominique Bonnet
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.